ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIA

Hellenic Institute for the Study of Sepsis0 个研究点目标入组 90 人开始时间: 2020年4月30日最近更新: 2022年8月8日

试验速览

暂无简介。

•Age =18 years
•Male of female gender
•Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent
•In case of women, unwillingness to remain pregnant during the study period achieved either by their partner using condom or by themselves using oral contraceptives.
•Confirmed infection by SARS-CoV-2 virus
•Infection of the upper respiratory tract or of the lower respiratory tract
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 45
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 45

•Age below 18 years
•Denial of written informed consent
•Presence of severe respiratory failure
•Intake of any macrolide for the current episode of infection under study
•Intake of hydroxychloroquine or chloroquine phosphate.
•Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 3 days
•Neutropenia defined as an absolute neutrophil count below 1,000/mm3
•Presence of any contraindications for the study drugs as stated in local label information
•QTc interval at rest ECG =500 msec or history of known congenital long QT syndrome
•Pregnancy or lactation

发起方